![]() |
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION
The Graduate School of Pharmaceutical Sciences, the University of Tokyo, Bunkyo-ku, Tokyo, Japan (Y.-J. L., H.K., Y.S.); Brain Imaging Project, National Institute of Radiological Sciences, Chiba, Japan (J.M., T.O., M.I., Y.N., S.O., T.S.); and Department of Medical Imaging, National Institute of Radiological Sciences, Chiba, Japan (R.N., K.S.)
P-glycoprotein (P-gp) is a major efflux transporter contributing to the efflux of a range of xenobiotic compounds at the blood-brain barrier (BBB). In the present study, we evaluated the P-gp function at the BBB using positron emission tomography (PET) in nonhuman primates. Serial brain PET scans were obtained in three rhesus monkeys after intravenous administration of [11C]verapamil under control and P-gp inhibition conditions ([PSC833 ([3'-keto-Me-Bmt1]-[Val2]-cyclosporin) 20 mg/kg/2 h]). The parent [11C]verapamil and its metabolites in plasma were determined by HPLC with a positron detector. The initial brain uptake clearance calculated from the integration plot was used for the quantitative analysis. After intravenous administration, [11C]verapamil was taken up rapidly into the brain (time to reach the peak, 0.58 min). The blood level of [11C]verapamil decreased rapidly, and it underwent metabolism with time. The inhibition of P-gp by PSC833 increased the brain uptake of [11C]verapamil 4.61-fold (0.141 versus 0.651 ml/g brain/min, p < 0.05). These results suggest that PET measurement with [11C]verapamil can be used for the evaluation of P-gp function at the BBB in the living brain.
Address correspondence to: Dr. Tetsuya Suhara, Brain Imaging Project, National Institute of Radiological Sciences, 9-1, Anagawa 4-Chome, Inage-ku, Chiba 263-8555, Japan. E-mail: suhara{at}nirs.go.jp
This article has been cited by other articles:
![]() |
Y. Kitamura, H. Koto, S. Matsuura, T. Kawabata, H. Tsuchiya, H. Kusuhara, H. Tsujimoto, and Y. Sugiyama Modest Effect of Impaired P-glycoprotein on the Plasma Concentrations of Fexofenadine, Quinidine, and Loperamide following Oral Administration in Collies Drug Metab. Dispos., May 1, 2008; 36(5): 807 - 810. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Takano, H. Kusuhara, T. Suhara, I. Ieiri, T. Morimoto, Y.-J. Lee, J. Maeda, Y. Ikoma, H. Ito, K. Suzuki, et al. Evaluation of In Vivo P-Glycoprotein Function at the Blood-Brain Barrier Among MDR1 Gene Polymorphisms by Using 11C-Verapamil J. Nucl. Med., September 1, 2006; 47(9): 1427 - 1433. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Ikoma, A. Takano, H. Ito, H. Kusuhara, Y. Sugiyama, R. Arakawa, T. Fukumura, R. Nakao, K. Suzuki, and T. Suhara Quantitative Analysis of 11C-Verapamil Transfer at the Human Blood-Brain Barrier for Evaluation of P-glycoprotein Function J. Nucl. Med., September 1, 2006; 47(9): 1531 - 1537. [Abstract] [Full Text] [PDF] |
||||